P-Shot® Priapus Shot in Orlando, FL: Platelet-Rich Plasma for Erectile Dysfunction & Sexual Wellness
Understanding Erectile Dysfunction The Vascular Root
Erectile dysfunction affects an estimated 30 million men in the United States, with prevalence rising sharply after age 40. The majority of ED cases in men over 40 have a primarily vascular origin: damage to the blood vessels, smooth muscle cells, and endothelial lining of the corpus cavernosum the paired erectile chambers that fill with blood during an erection prevents adequate arterial inflow and venous occlusion. Diabetes, hypertension, cardiovascular disease, smoking, and normal ageing all damage this vascular architecture progressively.
Oral PDE5 inhibitors (Viagra®, Cialis®) treat ED symptomatically: they amplify the nitric oxide signal that triggers smooth muscle relaxation, increasing blood flow for the pill’s duration. They do not repair the underlying tissue damage. When the damage is severe enough or the NO pathway too impaired pills fail to produce a satisfactory response. This is the gap that regenerative therapies like the P-Shot® aim to address: not managing symptoms, but attempting to rebuild the vascular and cellular architecture that makes healthy erections physiologically possible.
How the P-Shot® Works: Mechanism of Action
The P-Shot® is built on the same regenerative biology that has made PRP an established tool in orthopaedic surgery, wound care, and dermatology for over 30 years. Understanding how it works in penile tissue specifically helps set accurate expectations about what it can and cannot achieve
Step 1: Blood Draw and PRP Preparation A small volume of your blood (typically 20–60 mL) is drawn from your arm – similar to a routine blood test. The sample is placed into an FDA-cleared centrifuge separation system and spun at a precisely calibrated speed to separate blood components by density. Platelets, the small, anucleate cells your body uses to initiate tissue repair, concentrate in the plasma layer. The resulting platelet-rich plasma contains a platelet concentration approximately 5–10x higher than whole blood and, with it, a dense concentration of growth factors and bioactive proteins.
Step 2: Growth Factor Release and Cellular Signalling When PRP is injected into the corpus cavernosum, the platelets are activated by contact with collagen and other tissue proteins. Activated platelets degranulate, releasing a cascade of bioactive growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin-like growth factor (IGF-1). Each plays a different role in the regenerative process.
Step 3: Angiogenesis: New Blood Vessel Formation VEGF is the primary driver of angiogenesis, the formation of new capillaries and blood vessel networks. In penile tissue, angiogenesis is directly relevant to erectile function: more functional blood vessels mean more capacity for arterial inflow and improved veno-occlusion. Pre-clinical studies have consistently demonstrated that intracavernosal PRP promotes measurable angiogenesis in erectile tissue, with corresponding improvements in penile Doppler ultrasound parameters (peak systolic velocity) in clinical studies.
Step 4: Smooth Muscle and Endothelial Repair PDGF and TGF-β stimulate proliferation and migration of smooth muscle cells and fibroblasts within the corpus cavernosum. The trabecular smooth muscle that constitutes the majority of the erectile chambers must relax fully for an erection to occur, and smooth muscle cell loss is one of the hallmarks of vascular ED. PRP’s growth factors signal both repair of existing cells and recruitment of progenitor cells to restore smooth muscle architecture. Endothelial cells, which line the vascular walls and produce nitric oxide, also respond to PRP’s regenerative signals.
Step 5: Collagen Remodeling
FGF and TGF-β promote collagen remodelling, the replacement of damaged, fibrotic collagen deposits (which impede erection mechanics) with healthier, more elastic extracellular matrix. This mechanism is particularly relevant in Peyronie’s disease, where intracavernosal scar plaques create mechanical obstruction. PRP’s collagen-modulating effect is one reason it shows consistent results in published Peyronie’s disease studies.
Why Results Take Time — and Why Protocol Matters: Unlike botulinum toxin injections (MENZ Tox Shot™), which produce a pharmacological effect within days by blocking nerve signals, PRP’s regenerative effects are biological and gradual. Tissue repair, angiogenesis, and smooth muscle proliferation occur over weeks to months. This is why P-Shot® studies consistently show progressive improvement over 1–3–6 month evaluation periods rather than immediate results. It is also why treatment protocol injection volume, PRP concentration, number of sessions, and use of a penile vacuum device post-injection significantly impact outcomes. Variation in protocol is one reason the clinical literature shows heterogeneous results.
Potential Benefits of the P-Shot®
- Regenerative vs. symptomatic: Unlike pills that require per-encounter dosing, P-Shot® growth factors promote tissue repair and angiogenesis addressing the biological substrate of vascular ED rather than temporarily compensating for it
- Clinically meaningful improvement in responding patients: RCT data shows MCID achievement in 69–76% of PRP patients vs. 18–27% of placebo at 1–3 months, a treatment effect that is both statistically and clinically significant in responding populations
- No pre-planning required: When treatment produces benefit, improvements are present continuously spontaneous sexual activity without a dosing window or planning around a pill schedule
- 100% autologous, zero risk of rejection or allergic reaction: PRP is made entirely from your own blood. There is no foreign material, no synthetic compound, and no risk of immunological rejection or allergic reaction
- Excellent safety profile across all published studies: Across every major clinical trial to date, adverse events have been limited to mild, transient injection-site discomfort. No serious adverse events have been reported in any published P-Shot® study
- Evidence for Peyronie’s disease: Multiple studies show PRP reduces penile curvature, plaque burden, and pain associated with Peyronie’s disease, an area where non-surgical options are limited and often inadequate
- Enhanced sensitivity and sexual satisfaction Patient-reported outcome measures, including sexual satisfaction scores (IIEF Q6, 7, 8) and intercourse satisfaction (IIEF Q13, 14), improve alongside IIEF-EF scores in responding patients
- Combinability with other MENZ treatments Emerging evidence suggests P-Shot® combined with MENZ Wave® (acoustic wave therapy) may produce superior outcomes to either treatment alone
What the Clinical Research Shows: An Honest Assessment
Design: The first double-blind, randomized, placebo-controlled trial of intracavernosal PRP for ED. 60 men with mild-to-moderate ED randomized to 2 sessions of 10 mL PRP vs. placebo (1 month apart), using an FDA-approved separation system. No other ED treatment was permitted during the trial. Follow-up at 1, 3, and 6 months. Findings: At 6 months, the minimum clinically important difference (MCID) in IIEF-EF score was achieved by 69% of PRP patients vs. 27% of placebo — risk difference 42% (95% CI: 18–66, p < 0.001). Significant differences were also found at 1 and 3 months. No adverse events recorded during the entire study period. Limitations: Single center (Greece); relatively small sample (60); 6-month maximum follow-up; did not include a vacuum erection device protocol.
Design: Prospective, randomized, double-blind, placebo-controlled trial at the Desai Sethi Urology Institute, University of Miami — the most methodologically rigorous study to date. 61 men with mild-to-moderate organic ED (IIEF 11–25), normal testosterone, HbA1c < 9%. Randomized to 2 PRP injections vs. saline placebo (1 month apart). Primary outcome: MCID at 1 month post-second injection. Findings: No statistically significant difference between groups in MCID at primary endpoint — 58.3% in PRP vs. 60.6% in placebo (p not significant). No differences in IIEF at 1, 3, or 6 months. PRP was well-tolerated with no adverse events. Limitations: Relatively small sample (61); higher-than-expected placebo response rate; 1-month primary endpoint may be too early to capture regenerative effects; study used no vacuum erection device protocol. Investigators noted that combining PRP with acoustic wave therapy may improve outcomes and are conducting follow-up research. This study received a Best Abstract award at the AUA 2023 Annual Meeting.
Design: PROSPERO-registered systematic review and meta-analysis of 4 RCTs involving 413 patients, searched PubMed, Embase, Cochrane, and Web of Science to November 2023. Findings: PRP showed statistically significant advantage over placebo in MCID at months 1 (p = 0.03) and 6 (p = 0.008) — though not month 3 (p = 0.19, not significant). IIEF scores significantly favored PRP at all timepoints: 1 month (p < 0.00001), 3 months (p < 0.00001), and 6 months (p < 0.00001). Conclusion: 'PRP shows more effectiveness in treating ED compared to placebo.' Limitations: Only 4 RCTs available for inclusion; high heterogeneity across studies due to differing PRP preparations, injection volumes, and protocols.
Design: Comprehensive search across PubMed, Scopus, Web of Science, and ClinicalTrials.gov for placebo-controlled studies on intracavernosal PRP in primary organic ED. Meta-analysis of placebo-controlled studies only. Findings: PRP patients showed significantly higher IIEF-EF scores vs. placebo at all follow-up points: pooled mean difference of 2.99 (95% CI: 1.86–4.13) at 1 month; 2.85 (95% CI: 1.61–4.09) at 3 months; 3.21 (95% CI: 1.82–4.60) at 6 months. Conclusions: PRP intracavernosal injections demonstrated objective improvement or a tendency toward erectile function recovery in men with primary organic ED. Limitations: Small patient numbers; short-term follow-up; generalizability limited by heterogeneous protocols. Authors called for high-quality, large-scale standardized controlled trials before recommending definitive clinical use
Design: PRISMA-guideline systematic review of PRP in both ED and Peyronie's disease. PubMed and Scopus search through December 2023. 17 studies included (11 ED, 5 Peyronie's, 1 both), with 4 RCTs across a total of 1,099 patients. Findings — ED: Studies generally showed small to moderate benefits with mild and transient side effects and no major adverse events. Findings — Peyronie's Disease: PRP studies showed meaningful reductions in penile curvature, improvements in pain during intercourse, and improved IIEF scores. One prospective cohort (65 patients) found mean curvature reduction of 16–17° and IIEF improvement of 50–61% depending on curvature severity. Conclusion: 'Literature on PRP in andrology is limited and difficult to interpret due to variations in protocols and methodological drawbacks.' Further research is necessary to determine optimal preparation and treatment protocols.
Design: Comprehensive systematic review across PubMed, Cochrane, and ScienceDirect to February 2023. 517 articles were screened; 23 were included — 7 preclinical and 16 clinical studies. Findings: Preclinical data strongly support the regenerative role of PRP in erectile tissue. The first two available placebo-controlled RCTs showed 'promising efficacy and a lack of any adverse events. ' However, investigators noted that the Sexual Medicine Society of North America and AUA position that PRP for ED should currently only be used in the context of clinical trials. Limitations: The evidence base is still immature; standardised treatment protocols are lacking; optimal PRP concentration, injection volume, and session frequency have not yet been established.
69%
of Jeuveau® Patients Achieved Complete Results (≥2-Grade Improvement) by Day 30
50%
of Patients Begin Showing Visible Improvement as Early as Day 2
94%
Response Rate in Patients with Skin of Color at Day 30 — Statistically Equivalent to Lighter Skin Types
74%
of Surveyed Patients Prefer Jeuveau® After Treatment
Who Is the P-Shot® For?
Candidacy assessment is the most important part of the P-Shot® process. The clinical evidence shows that P-Shot® works best in specific patient profiles. Dr. J’s consultation is designed to determine where you fall on this spectrum honestly — not to sell you a treatment that isn’t the right fit
Men Who Are Typically Good Candidates:
- Have mild-to-moderate erectile dysfunction the patient population in which the RCT evidence is strongest
- Have vasculogenic (vascular-origin) ED with evidence of compromised penile blood flow — a tissue repair approach is biologically rational for this profile
- Have not responded adequately to oral PDE5 inhibitors (Viagra, Cialis) or are seeking an approach that addresses root causes rather than symptoms
- Have Peyronie’s disease penile curvature, scar plaques, and pain and are seeking non-surgical treatment options
- Are interested in a regenerative, biologically-based approach as part of a comprehensive men’s wellness strategy
- Are seeking improved sexual sensitivity and performance optimization, not solely ED treatment
- Have platelet counts and overall blood health sufficient for effective PRP preparation Dr. J assesses this at consultation
- Are men in the 35–70 age range with primarily organic (rather than purely psychogenic) ED
P-Shot® Is Typically Less Appropriate If You:
- Have primarily psychogenic ED, performance anxiety, relationship issues, or psychological factors as the dominant cause; therapy, hormone optimization, or MENZ Wave® may be better first steps
- Have severe vasculogenic ED with extensive vascular disease; the biological substrate may be too compromised for PRP to produce meaningful regeneration. MENZ Tox Shot™ or MENZ Wave® may be more effective
- Have a platelet disorder, are on anticoagulant therapy that cannot be safely paused, or have active infection at the injection site
- Have not yet tried first-line treatments: If you have never tried PDE5 inhibitors and have no contraindication, oral therapy should be evaluated first
- Have active prostate cancer or other conditions that may be stimulated by growth factors Dr J will assess this during your consultation
- Are looking for a permanent cure P-Shot® produces improvement for the duration of its regenerative effect (typically 6–18 months); re-treatment maintains benefit
Your Consultation Is the Most Important Step
treatment. Dr J will review your medical history, ED aetiology, prior treatment history, vascular health, hormonal status, and individual goals to determine whether P-Shot® is your best option as a standalone treatment, combined with MENZ Wave® or MENZ Tox Shot™, or as a component of a broader MENZ wellness protocol. He will not recommend P-Shot® if another approach is more likely to produce meaningful results for you. Every consultation is free, completely private, and conducted by Dr J personally
Your P-Shot® Appointment Step by Step
Step 1: Free Confidential Consultation: Dr J conducts a thorough private medical intake. He reviews your ED history, severity and duration; prior treatments and their outcomes; medical history (diabetes, hypertension, cardiovascular disease, medications); testosterone status, if relevant; and sexual health goals. He explains P-Shot® in clinical detail; presents the evidence honestly, including limitations; and helps you evaluate whether it is the right fit — alone or in combination with other MENZ treatments.
Step 2: Medical Assessment and Candidacy Confirmation: Dr J evaluates your vascular health, hormonal profile, and platelet health. He reviews any recent blood work and may request additional labs if needed to confirm your candidacy and optimise your PRP yield. He discusses realistic expectations based on your specific clinical profile and explains what combination protocol, if any, he would recommend in addition to P-Shot®.
Step 3: Blood Draw: On the day of your P-Shot® appointment, a small volume of your blood, typically 20–60 mL depending on protocol, is drawn from your arm using a standard venipuncture technique. This is similar to a routine blood test. No fasting is required. The entire draw takes 2–3 minutes.
Step 4: PRP Preparation: Your blood is placed into an FDA-cleared centrifuge separation system and spun for approximately 10–15 minutes. This separates blood components by density and concentrates the platelet cells, which are rich in the growth factors responsible for tissue repair, into the plasma layer. The resulting PRP typically contains a platelet concentration 5–10 times higher than whole blood. The quality and concentration of PRP vary by preparation system, which is why Dr J uses FDA-cleared equipment to optimise the final injectable.
Step 5: Topical Anaesthesia: A topical numbing cream (EMLA or equivalent) is applied to the penis and given 15–20 minutes to take full effect. Most patients report that this preparation eliminates meaningful discomfort from the injection process. A penile ring band is placed temporarily at the base of the penis during the injection to improve PRP distribution and retention within the erectile tissue – a technique used in the clinical trials that produced positive outcomes.
Step 6: The Injection: Dr J uses a fine-gauge needle to administer the concentrated PRP into specific anatomical areas of the penis, including the corpus cavernosum, using precise technique and depth control. The injection itself takes 5–10 minutes. Patients typically describe the experience as mild pressure rather than pain. No sedation is required. Published clinical studies record adverse events limited to mild, transient injection-site discomfort in a small minority of patients; no systemic adverse events have been reported across any major trial.
Step 7: Vacuum Erection Device (VED) Protocol: Following the injection, and for the next 4–6 weeks at home, Dr J recommends use of a VED (vacuum erection device / penis pump) for 10–15 minutes daily. Evidence from clinical practice suggests that mechanical traction during the regenerative window while growth factor activity is highest enhances the distribution of PRP-delivered signals throughout penile tissue and may improve outcomes. Patients who consistently use the VED post-procedure tend to achieve better results than those who do not.
Step 8: Results Timeline and Follow-Up: The regenerative process takes time. Early responders may notice improved sensitivity or erection quality within 2–4 weeks, but the full benefit typically develops over 2–3 months as angiogenesis, smooth muscle repair, and collagen remodelling progress. Most responding patients report peak benefit at 2–4 months, with effects lasting 6–18 months depending on individual factors. Dr J will schedule a follow-up assessment and discuss whether a repeat injection, a combination with MENZ Wave®, or a full multimodal protocol is appropriate to maintain and build on your results.
P-Shot® vs. Oral ED Medications vs. MENZ Tox Shot™ Clinical Comparison
P-Shot® (PRP ICI)
Mechanism: Regenerative growth factors promote tissue repair, angiogenesis, smooth muscle restoration,
Addresses root cause: Aims to repair vascular and smooth muscle tissue
Results onset: Gradual 2–4 weeks early signs; full benefit 2–3 months
Duration: 6–18 months per cycle
Spontaneity: Continuous no pre-planning
Foreign substance: 100% autologous from your own blood
Peyronie’s evidence: Multiple studies show curvature reduction and IIEF improvement
Adverse events: Mild transient injection-site discomfort only; no systemic events in any trial
Works for pill non-responders: Studied in this population different mechanism
Best combined with: MENZ Wave® (acoustic wave); MENZ Tox Shot™; hormone optimization
Oral PDE5-I (Viagra® / Cialis®)
Mechanism: Symptomatic amplifies NO signal for 4–6 hrs; no tissue repair
Addresses root cause: Symptomatic only
Results onset: Fast 30–60 min per dose
Duration: 4–6 hours per pill (sildenafil); 24–36 hrs (tadalafil)
Spontaneity: Must plan 30–60 min before activity
Foreign substance: Synthetic pharmaceutical compound
Peyronie’s evidence: Not indicated
Adverse events: Headache, flushing, low BP, vision changes; dangerous with nitrates
Works for pill non-responders: By definition, not effective for this group
Best combined with: Can be combine with P-Shot® or MENZ Tox Shot™ in some cases
MENZ Tox Shot™ (BoNT-A ICI)
Mechanism: Pharmacological blocks sympathetic nerve constriction at source; no tissue repair
Addresses root cause: Reduces sympathetic constriction; does not regenerate tissue
Results onset: 2–4 weeks for effect onset; progressive
Duration: 3–9+ months per session
Spontaneity: Continuous no pre-planning
Foreign substance: Botulinum toxin protein not autologous
Peyronie’s evidence: No evidence in Peyronie’s
Adverse events: Mild transient penile discomfort (1.5–6%) no systemic adverse events
Works for pill non-responders: Specifically studied in PDE5-I non-responders strong evidence
Best combined with: P-Shot® (complementary mechanisms); MENZ Wave®; PDE5 inhibitors (synergy shown)
Explore the Complete MENZ Men's Sexual Wellness Suite
P-Shot® is most effective as part of a comprehensive men’s sexual health strategy. Dr J has designed a full suite of evidence-based treatments that can be combined for personalised, multi-modal care:
MENZ Tox Shot™: Intracavernosal botulinum toxin injection pharmacologically blocks sympathetic nerve signals to relax penile smooth muscle and increase blood flow. Works when pills fail. Particularly strong evidence for vasculogenic ED and PDE5-I non-responders. Complementary to P-Shot® (different mechanisms).
MENZ Wave®: Low-intensity extracorporeal acoustic wave therapy (Li-ESWT) stimulates angiogenesis and improves penile vascular health at the tissue level through mechanical shockwave energy. Strong RCT evidence. Recommended as a combination with P-Shot® by leading researchers. May enhance and extend P-Shot® results.
MENZ Booster®: Hormone and wellness optimisation of testosterone, DHEA, and related markers. Low testosterone is a major contributor to ED, low libido, fatigue, and reduced response to other ED treatments in men 40+. Addressing hormonal deficiency is often the most impactful single intervention in the right patient.
MENZ Shot™: PRP injection for sexual health using a slightly different anatomical protocol.
MENZ Grow®: Non-surgical enhancement treatment.
Erectile Dysfunction Comprehensive : Evaluation A full medical assessment of ED aetiology (vascular, hormonal, neurological, and psychogenic) with a personalised treatment roadmap. The starting point for men who want to understand their ED before choosing a treatment path.
O-Shot® (for women): The female equivalent of regenerative PRP sexual wellness treatment, intravaginal PRP for sexual dysfunction, sensitivity, and urinary incontinence.
P-Shot® Frequently Asked Questions
The P-Shot® (Priapus Shot®) uses platelet-rich plasma from your own blood not a synthetic drug to promote tissue regeneration within the erectile chambers of the penis. PRP’s concentrated growth factors (VEGF, PDGF, TGF-β, and others) stimulate new blood vessel formation, smooth muscle repair, and endothelial cell regeneration. Oral ED medications like Viagra and Cialis work symptomatically: they amplify the nitric oxide signal for a few hours around dosing but do not change the underlying tissue. P-Shot® aims to work regeneratively: improving the biological architecture of the penis over time. Results develop gradually over weeks to months and may last 6–18 months rather than hours.
Book Your Free P-Shot® Consultation in Orlando
Erectile dysfunction is one of the most common and most undertreated health conditions in men over 40. Most men spend years living with it before seeking help. If you’ve reached this page, you’re already ahead of that curve. The P-Shot® at Dr J Anti-Ageing Clinic may be the right next step — or it may be that another approach in the MENZ suite is the better clinical fit. The consultation is the only way to know.
Dr. J’s free consultation is completely private, completely judgement-free, and conducted by Dr J personally — not a salesperson, not a nurse, not a patient coordinator. You will leave with a clear, honest picture of your options, your candidacy, and what realistic outcomes look like for your situation.